Last reviewed · How we verify
Rapamune Pill
At a glance
| Generic name | Rapamune Pill |
|---|---|
| Also known as | Sirolimus |
| Sponsor | Shahid Beheshti University of Medical Sciences |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Anemia
- Myalgia
- Nausea
- Platelet count decreased
- Hyperglycemia
- Hypertriglyceridemia
- Rash acneiform
- Diarrhea
- Bronchial infection
- Lung infection
- Cholesterol high
- Creatinine increased
Key clinical trials
- Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate Cancer (PHASE2)
- Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer (PHASE1, PHASE2)
- The Role of Sirolimus in Preventing Functional Decline in Older Adults (PHASE2)
- Metformin and Molecular Aging in Prediabetes (NA)
- RESTOR: PK/PD mTORi Inhibition in Older Adults (EARLY_PHASE1)
- Low Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19 (PHASE3)
- Sirolimus Monotherapy in the Treatment of Antiphospholipid Antibody Related Thrombocytopenia (PHASE4)
- Allo HSCT Using RIC and PTCy for Hematological Diseases (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rapamune Pill CI brief — competitive landscape report
- Rapamune Pill updates RSS · CI watch RSS
- Shahid Beheshti University of Medical Sciences portfolio CI